Invesco Ltd. Has $293.43 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Invesco Ltd. grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 16.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,070,384 shares of the medical equipment provider's stock after purchasing an additional 572,187 shares during the quarter. Invesco Ltd. owned about 1.80% of Hologic worth $293,434,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group increased its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after buying an additional 145 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its holdings in shares of Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after acquiring an additional 169 shares during the last quarter. UMB Bank n.a. raised its stake in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after acquiring an additional 188 shares during the period. Finally, Capital Investment Counsel Inc lifted its holdings in Hologic by 3.6% during the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after purchasing an additional 200 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

HOLX has been the topic of several research analyst reports. Stephens reissued an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Citigroup reduced their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Evercore ISI lowered their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Finally, Royal Bank of Canada decreased their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic presently has an average rating of "Hold" and an average price target of $84.62.

Hologic Trading Down 1.4 %

Shares of NASDAQ HOLX traded down $0.83 during midday trading on Wednesday, reaching $57.03. The stock had a trading volume of 697,625 shares, compared to its average volume of 1,918,450. The company's 50 day moving average price is $62.04 and its 200 day moving average price is $71.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a twelve month low of $56.27 and a twelve month high of $84.67. The firm has a market cap of $12.80 billion, a price-to-earnings ratio of 17.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.